Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8443-8448

  van Gils, Marit J ^a   Edo Matas, Diana ^a   Bowles, Emma J ^b   Burger, Judith A ^a   Stewart Jones, Guillaume B ^b   Schuitemaker, Hanneke ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; NEUTRALIZING ANTIBODY; PROTEIN VP1; PROTEIN VP2; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHIMERA; CONTROLLED STUDY; CROSS REACTION; EVOLUTIONARY ADAPTATION; FOLLOW UP; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79961179950     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05214-11     Document Type: Article

References (36)

1. Barouch, D. H., and N. L. Letvin. 2004. HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Lancet 364:10-11.
2. + T cell decline. Proc. Natl. Acad. Sci. U. S. A. 97:1269-1274.
3. Bunnik, E. M. et al. 2010. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16:995-997.
4. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
5. Edo-Matas, D. et al. 2010. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405:492-504.
6. Frost, S. D. et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
7. Gaschen, B. et al. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
8. Gray, E. S. et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81:6187-6196.
9. Ho, D. D. et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
10. Jansson, M. et al. 1999. Coreceptor usage and RANTES sensitivity of nonsyncytium-inducing HIV-1 isolates obtained from patients with AIDS. J. Hum. Virol. 2:325-338.
11. Jansson, M. et al. 1996. Sensitivity to inhibition by β-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc. Natl. Acad. Sci. U. S. A. 93:15382-15387.
12. Koning, F. A. et al. 2003. Decreasing sensitivity to RANTES neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 188:864-872.
13. Kwa, D., J. Vingerhoed, B. Boeser, and H. Schuitemaker. 2003. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J. Infect. Dis. 187:1397-1403.
14. Kwong, P. D. et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
15. Mahalanabis, M. et al. 2009. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83:662-672.
16. Malim, M. H., and M. Emerman. 2001. HIV-1 sequence variation: drift, shift, and attenuation. Cell 104:469-472.
17. Martin, N. et al. 2010. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84:3516-3527.
18. Mittler, J. E., M. Markowitz, D. D. Ho, and A. S. Perelson. 1999. Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS 13:1415-1417.
19. Moore, P. L. et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
20. Navis, M. et al. 2007. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J. Immunol. 179: 3133-3143.
21. Pinter, A. 2007. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr. HIV Res. 5:542-553.
22. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
23. Repits, J. et al. 2005. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86:2859-2869.
24. Repits, J. et al. 2008. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 379:125-134.
25. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
26. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
27. Rong, R. et al. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81:1350-1359.
28. Rong, R. et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
29. Sagar, M., X. Wu, S. Lee, and J. Overbaugh. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
30. Shankarappa, R. et al. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73:10489-10502.
31. Sterjovski, J. et al. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
32. van Gils, M. J. et al. 18 May 2011, posting date. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. [Epub ahead of print.] doi:10.1128/JVI.00268-11.
33. van Gils, M. J. et al. 2010. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 84:3576-3585.
34. van Rij, R. P. et al. 2000. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J. Clin. Invest. 106:1039-1052.
35. Wei, X. et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
36. Wei, X. et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.